hotspot -WSS

hotspot

author：comprehensive 2025-10-01 22:57:45 - browse：93575

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Elevance, SCAN deals highlight health insurer acquisition scrutiny

hotspot

WSS

Biotech stock slump in 2023: awaiting the turnaround

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

FDA panel to weigh approval of NurOwn, controversial ALS drug

Intarcia’s device

Elevance, SCAN deals highlight health insurer acquisition scrutiny

It's been 20 years since Dolly the sheep. Where's my clone?

focus

hotspot

focus

Supreme Court strikes down use of affirmative action

Second xenotransplant done with gene

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Ukraine and a new approach to mental health in war

Novavax promises a turnaround & Lilly roils the obesity market

Hospitals are piloting generative AI tools as regulators play catch

Hepatitis C has a cure — but many Americans still lack access to it

Microbiome research is starting to find links to chronic diseases

Psychedelics group wrestles with new pharma identity

FDA panel to weigh approval of NurOwn, controversial ALS drug

knowledge

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Ukraine seeks to reclaim its role as a hub for clinical trials

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Second xenotransplant done with gene

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

explore

focus

hotspot

hotspot